CRISPR Therapeutics AG - Company Profile
Powered by
All the data and insights you need on CRISPR Therapeutics AG in one report.
- Save hours of research time and resources with
our up-to-date CRISPR Therapeutics AG Strategy Report
- Understand CRISPR Therapeutics AG position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
CRISPR Therapeutics AG (CRISPR) is a gene editing company. It focuses on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a gene-editing technology that modifies, deletes, or corrects disease-causing abnormalities at its genetic sources. Its major development programs include ex vivo programs involving gene editing of hematopoietic cells; ex vivo programs in immuno-oncology; in vivo programs targeting the liver and additional in vivo programs targeting other organ systems including muscle and lung. It has research and development operations in Cambridge, Massachusetts, the US and business operations in London, the UK. CRISPR is headquartered in Zug, Switzerland.
CRISPR Therapeutics AG premium industry data and analytics
Products and Services
Products |
---|
Pipeline |
Hemoglobinopathies: |
Exa-cel: Beta Thalasemia |
XYZ |
XYZ |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Regulatory Approval | In February, the company received conditional marketing authorization to CASGEVY (exagamglogene autotemcel [exa-cel]) from the European Commission. |
2023 | Regulatory Approval | In June, the company and Vertex Pharmaceuticals' Biologics License Applications were accepted by the US FDA for the investigational treatment exagamglogene autotemcel for severe sickle cell disease and transfusion-dependent beta thalassemia. |
2023 | Contracts/Agreements | In March, the company signed a new non-exclusive licensing agreement with Vertex Pharmaceuticals to expedite the development of its hypoimmune cell therapies to treat type 1 diabetes (T1D). |
Competitor Comparison
Key Parameters | CRISPR Therapeutics AG | Sangamo Therapeutics Inc | Poseida Therapeutics Inc | Precision Biosciences Inc | UniQure NV |
---|---|---|---|---|---|
Headquarters | Switzerland | United States of America | United States of America | United States of America | Netherlands |
City | Zug | Richmond | San Diego | Durham | Amsterdam |
State/Province | - | California | California | North Carolina | Noord-Holland |
No. of Employees | 407 | 405 | 330 | 109 | 480 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Samarth Kulkarni | Chief Executive Officer; Chairman; Director | Executive Board | 2023 | - |
Raju Prasad, Ph.D | Chief Financial Officer | Senior Management | 2023 | - |
Megan Wherry Menner | Head - Human Resources | Senior Management | - | - |
Jon Terrett | Head - Research | Senior Management | - | - |
James R. Kasinger | General Counsel; Secretary | Senior Management | 2017 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer